oral selective DNA-PK kinase inhibitor

synergy with radiotherapy in model

from library screen

Journal of Medicinal Chemistry

Bayer AG, Berlin, Germany

The Bayer DNA-PK inhibitor, BAY-8400, is an orally active and selective DNA-PK kinase inhibitor that synergistically enhances the efficacy of radiotherapeutics in xenograft models. The program started with a campaign…

 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.